{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:15:56Z","timestamp":1792844156440,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jchromb.2026.124926","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:23:15Z","timestamp":1768868595000},"page":"124926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An optimized HPLC-MS\/MS assay for uracil and dihydrouracil in plasma: Improving dihydropyrimidine dehydrogenase phenotyping for individualized fluoropyrimidine treatment"],"prefix":"10.1016","volume":"1272","author":[{"given":"Yahia","family":"Bennani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Samer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Koessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Daali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2026.124926_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","article-title":"Development and validation of a rapid and sensitive UPLC\u2013MS\/MS method for determination of uracil and dihydrouracil in human plasma","volume":"126","author":"Jacobs","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.124926_bb0015","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2026.124926_bb0020","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3332\/ecancer.2022.1344","article-title":"Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door","volume":"16","author":"Donadio","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.jchromb.2026.124926_bb0025","series-title":"StatPearls [Internet]. Treasure Island","article-title":"Fluorouracil","author":"Casale","year":"2024"},{"key":"10.1016\/j.jchromb.2026.124926_bb0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","article-title":"Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?","volume":"28","author":"Mercier","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jchromb.2026.124926_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial Pyrimidinemia and Pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2026.124926_bb0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"D\u00e9pistage du d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase (DPD) et s\u00e9curisation des chimioth\u00e9rapies \u00e0 base de fluoropyrimidines\u202f: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull. Cancer (Paris)"},{"key":"10.1016\/j.jchromb.2026.124926_bb0045","first-page":"181","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.jchromb.2026.124926_bb0050","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical pharmacogenetics implementation consortium guidelines for Dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jchromb.2026.124926_bb0055","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jchromb.2026.124926_bb0060","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jchromb.2026.124926_bb0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate dihydrouracil\/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice","volume":"823","author":"Remaud","year":"2005","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2026.124926_bb0070","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.clinbiochem.2016.07.004","article-title":"Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies","volume":"49","author":"Galarza","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jchromb.2026.124926_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13699","article-title":"Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing","volume":"17","author":"Turner","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2026.124926_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jchromb.2026.124926_bb0085","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.124926_bb0090","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbadis.2016.01.009","article-title":"Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene","volume":"1862","author":"van","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.jchromb.2026.124926_bb0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-023-03466-8","article-title":"Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapy","volume":"79","author":"Doornhof","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.124926_bb0100","first-page":"507","article-title":"Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver","volume":"2","author":"Chazal","year":"1996","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jchromb.2026.124926_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejca.2022.11.028","article-title":"Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency","volume":"181","author":"Etienne-Grimaldi","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jchromb.2026.124926_bb0110","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s00216-012-6614-2","article-title":"Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination","volume":"405","author":"Pluim","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2026.124926_bb0115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","article-title":"The uracil breath test in the assessment of Dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2026.124926_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jchromb.2026.124926_bb0125","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/bcp.15536","article-title":"Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency","volume":"89","author":"Maillard","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.124926_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115027","article-title":"Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions","volume":"221","author":"van den Wildenberg","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.124926_bb0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00280-023-04518-7","article-title":"Assay performance and stability of uracil and dihydrouracil in clinical practice","volume":"91","author":"Knikman","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.124926_bb0140","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FTD.0000000000000768","article-title":"Phenotyping of uracil and 5-fluorouracil metabolism using LC-MS\/MS for prevention of toxicity and dose adjustment of fluoropyrimidines","volume":"42","author":"Tafzi","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2026.124926_bb0145","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0000000000000788","article-title":"5-fluorouracil response prediction and blood level\u2013guided therapy in oncology: existing evidence fundamentally supports instigation","volume":"42","author":"Chavani","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2026.124926_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0009-9120(02)00303-X","article-title":"Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay","volume":"35","author":"Liem","year":"2002","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jchromb.2026.124926_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122038","article-title":"Automatic quantification of uracil and dihydrouracil in plasma","volume":"1142","author":"Robin","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2026.124926_bb0160","author":"European Medicines Agency (EMA)"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:16:48Z","timestamp":1789229808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S1570023226000152"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.124926","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An optimized HPLC-MS\/MS assay for uracil and dihydrouracil in plasma: Improving dihydropyrimidine dehydrogenase phenotyping for individualized fluoropyrimidine treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.124926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124926"}}